drugset / Trial / NCT01010802
Safety Study of Erythropoietin (EPO) in Parkinson's Disease
Phase 1
Completed
10 enrolled
International Center for Neurological Restoration, Cuba
Centro de Immunologia Molecular, Cuba · collab
NaSingle-groupOpen-labelPrevention
Summary
The purpose of this study is to determine whether recombinant human Erythropoietin (EPOrh) is safe in the treatment of patients with Parkinson's Disease.
Timeline
- Start
- 2008-08
- Primary completion
- 2009-05
- Completion
- 2009-05
Publications
- Results Pedroso I, Bringas ML, Aguiar A, Morales L, Alvarez M, Valdes PA, Alvarez L. Use of Cuban recombinant human erythropoietin in Parkinson's disease treatment. MEDICC Rev. 2012 Jan;14(1):11-7. doi: 10.37757/MR2012V14.N1.4.
- Results Pedroso I, Garcia M, Casabona E, Morales L, Bringas ML, Perez L, Rodriguez T, Sosa I, Ricardo Y, Padron A, Amaro D. Protective Activity of Erythropoyetine in the Cognition of Patients with Parkinson's Disease. Behav Sci (Basel). 2018 May 21;8(5):51. doi: 10.3390/bs8050051. eCollection 2018 May.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Erythropoietin human recombinant | Unknown | 60 iu/kg | Subcutaneous |